AGC Asahi Glass agreed to acquire CMC Biologics, a contract manufacturing and development organization (CDMO), in a deal that is expected to close next month. AGC manufactures glass, chemicals, and high-tech materials.

“I am thrilled that we now will be a central part of AGC's pharmaceutical services business, with biologic manufacturing operations in Europe, U.S.A., and Asia,” said David Kauffmann, chairman of CMC Biologics.  “AGC's commitment to best technology solutions and longtime partnership with clients align so well with CMC Biologics' mission to be the preferred biologics CDMO service partner for the world's top pharmaceutical and biotech companies.” 

CMC Biologics will retain its distinct brand and independence and continue to provide services to the biopharma marketplace, according to company officials.